JP2013538868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538868A5 JP2013538868A5 JP2013532276A JP2013532276A JP2013538868A5 JP 2013538868 A5 JP2013538868 A5 JP 2013538868A5 JP 2013532276 A JP2013532276 A JP 2013532276A JP 2013532276 A JP2013532276 A JP 2013532276A JP 2013538868 A5 JP2013538868 A5 JP 2013538868A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- quinoline
- phenylethyl
- phenoxy
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000000813 microbial effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- XCZMUTGHJBFKPM-UHFFFAOYSA-N 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydropyrrolo[3,2-c]quinoline Chemical compound C1=C2C=3N(CCC=4C=CC=CC=4)CCC=3C(C)=NC2=CC=C1OC1=CC=CC=C1 XCZMUTGHJBFKPM-UHFFFAOYSA-N 0.000 claims description 7
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 244000005700 microbiome Species 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011221 initial treatment Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- TUBLQASFQYGWFS-UHFFFAOYSA-N 8-phenoxy-1-(2-phenylethyl)-2,3-dihydropyrrolo[3,2-c]quinoline Chemical compound C1CC2=CN=C3C=CC(OC=4C=CC=CC=4)=CC3=C2N1CCC1=CC=CC=C1 TUBLQASFQYGWFS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- JVNKZPITIPHJQO-UHFFFAOYSA-N methanesulfonic acid;4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydropyrrolo[3,2-c]quinoline Chemical compound CS(O)(=O)=O.C1=C2C=3N(CCC=4C=CC=CC=4)CCC=3C(C)=NC2=CC=C1OC1=CC=CC=C1 JVNKZPITIPHJQO-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1016999.3A GB201016999D0 (en) | 2010-10-08 | 2010-10-08 | Novel composition |
| GB1016999.3 | 2010-10-08 | ||
| GBGB1107756.7A GB201107756D0 (en) | 2011-05-10 | 2011-05-10 | Novel composition |
| GB1107756.7 | 2011-05-10 | ||
| PCT/GB2011/051931 WO2012046078A1 (en) | 2010-10-08 | 2011-10-07 | Novel composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538868A JP2013538868A (ja) | 2013-10-17 |
| JP2013538868A5 true JP2013538868A5 (https=) | 2015-12-17 |
Family
ID=44872428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532276A Pending JP2013538868A (ja) | 2010-10-08 | 2011-10-07 | 新規な組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130245060A1 (https=) |
| EP (1) | EP2624817A1 (https=) |
| JP (1) | JP2013538868A (https=) |
| CN (1) | CN103249402A (https=) |
| CA (1) | CA2811568A1 (https=) |
| WO (1) | WO2012046078A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201107755D0 (en) * | 2011-05-10 | 2011-06-22 | Helperby Therapeutics Ltd | Novel compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1057131A (en) * | 1963-02-21 | 1967-02-01 | Boots Pure Drug Co Ltd | New antibacterial and antifungal compositions |
| KR100374462B1 (ko) | 1993-10-22 | 2003-06-09 | 스미스클라인 비참 코포레이션 | 신규조성물 |
| ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
| GB9620985D0 (en) * | 1996-10-08 | 1996-11-27 | Gillette Co | Ball point pen |
| EP0966974B1 (en) * | 1998-01-13 | 2004-12-01 | Daiichi Suntory Pharma Co., Ltd. | Antibacterial composition for topical administration containing faropenem |
| US6974585B2 (en) | 2001-08-01 | 2005-12-13 | Medlogic Global Limited | Durable multi-component antibiotic formulation for topical use |
| JP2007502861A (ja) * | 2003-05-01 | 2007-02-15 | レプリダイン・インコーポレーテッド | 抗菌方法及び組成物 |
| JP5460947B2 (ja) * | 2003-09-03 | 2014-04-02 | グラクソ グループ リミテッド | 新規調製方法、塩、組成物及び使用 |
| US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| KR20070091613A (ko) | 2004-11-08 | 2007-09-11 | 그렌마크 파머수티칼스 엘티디. | 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물 |
| GB0522715D0 (en) * | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
| GB0709513D0 (en) * | 2007-05-17 | 2007-06-27 | Helperby Therapeutics Ltd | Topical formulations |
| CN101668511A (zh) * | 2007-02-28 | 2010-03-10 | 阿西克斯医疗公司 | 正常化睑板腺分泌的方法和化合物 |
| CA2790827A1 (en) * | 2010-03-01 | 2011-09-09 | Photocure Asa | Cosmetic compositions |
| DK2600869T3 (da) * | 2010-08-05 | 2020-11-16 | Helperby Therapeutics Ltd | Kombination af en pyrroloquinolinforbindelse og et beta-lactam-antimikrobielt middel, mupirocin eller chlorhexidin |
-
2011
- 2011-10-07 US US13/824,986 patent/US20130245060A1/en not_active Abandoned
- 2011-10-07 WO PCT/GB2011/051931 patent/WO2012046078A1/en not_active Ceased
- 2011-10-07 CN CN2011800593868A patent/CN103249402A/zh active Pending
- 2011-10-07 CA CA2811568A patent/CA2811568A1/en not_active Abandoned
- 2011-10-07 JP JP2013532276A patent/JP2013538868A/ja active Pending
- 2011-10-07 EP EP11773310.5A patent/EP2624817A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7668793B2 (ja) | 抗菌オルガノシラン | |
| US9034918B2 (en) | Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections | |
| Hemmati et al. | Antibacterial and antibiofilm potentials of vancomycin-loaded niosomal drug delivery system against methicillin-resistant Staphylococcus aureus (MRSA) infections | |
| EP2496215B1 (en) | Antimicrobial and anti-acne formulations | |
| JP6783476B2 (ja) | ムピロシン及びネオマイシンを含む抗菌組成物 | |
| CN103384519B (zh) | 抗微生物的组合物 | |
| CN110753549A (zh) | 双磷脂素凝胶制剂及其用途 | |
| Hemmati et al. | Niosomal‐based drug delivery platforms: a promising therapeutic approach to fight staphylococcus aureus drug resistance | |
| El-Gayar et al. | Antivirulence and wound healing effects of royal jelly and garlic extract for the control of MRSA skin infections | |
| KR20230008873A (ko) | 항균성 화합물 및 이의 사용 방법 | |
| US20090081153A1 (en) | Combination of synthetic antimicrobial polymers and sesquiterpenoid compounds | |
| JP2019509353A (ja) | 微生物バイオフィルムに関連する皮膚状態および疾患の処置 | |
| JP2020533417A (ja) | 抗菌組成物 | |
| CN107073124B (zh) | 增效的抗微生物剂 | |
| JP2013538868A5 (https=) | ||
| KR102620652B1 (ko) | 미생물 콜로니화의 조절을 위한 치환된 톨란 | |
| RU2672869C1 (ru) | Антибактериальное средство на основе бактериофага | |
| ES2902456T3 (es) | Composiciones farmacéuticas que comprenden agentes antibacterianos | |
| Zisi et al. | Iodine-lithium-alpha-dextrin (ILαD) against Staphylococcus aureus skin infections: a comparative study of in-vitro bactericidal activity and cytotoxicity between ILαD and povidone-iodine | |
| Hernandez-Romero et al. | Rifampicin and N-acteylcisteyne inhibit oral bacterial growth and biofilm formation | |
| CN106163519A (zh) | 包含抗菌剂的药物组合物 | |
| JP2011093873A (ja) | 化粧料に用いる被覆処理粉体 | |
| WO2024229525A1 (en) | Dysregulation of planktonic bacterial metabolism | |
| CN105078951A (zh) | 杏仁酸在抑制痤疮杆菌中的用途 | |
| US20180228758A1 (en) | Compositions and methods to treat infected ear conditions |